Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises

Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-mo

On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the anal

Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN),

Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year.CF Revenue: Global CF revenue grew 11%

Company to host investor conference call and webcast at 4:30 p. m. ET. Cambridge, Massachusetts, Aug

Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raise

Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-A

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se

ProMIS Neurosciences Inc. (NASDAQ:PMN) reported positive blinded six-month interim safety and biomar

ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug can

Chardan Capital analyst Keay Nakae maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and rai

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

AMKR: -9% | Amkor Technology shares are trading lower after the company reported Q2 financial result

In the blinded interim analysis evaluating 136 AD patients, PMN310 was observed to have a favorable

No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rate

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess

Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN),

Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#

The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 230.2% upside in the

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ:PM

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) w

Promis Neurosciences (PMN) might move higher on growing optimism about its earnings prospects, which

The average of price targets set by Wall Street analysts indicates a potential upside of 231.8% in P

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) w

BRISBANE, AUS, June 2, 2026 - (ACN Newswire) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX:

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive lic

CAMBRIDGE, Mass. , May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clini

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the anal

Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exer

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(3.11) per share which missed the an

ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-gene

Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lower

6,090,075 Common Shares were sold at a price of $10.77 per Common Share, 100,000 Pre-Funded Warrants

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insi

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and a

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ProMIS Neurosciences (NASDAQ:PMN) wi